{"title":"Treatment of Attention Deficit Hyperactivity Disorder in Children With Medical Comorbidities","authors":"A. Kledzik, D. Dunn","doi":"10.1097/01.IDT.0000377465.94323.2d","DOIUrl":null,"url":null,"abstract":"der (ADHD) in children was analyzed in several epidemiologic studies and estimated to be approximately 7%. Follow-up studies estimate that 60% to 85% of these children will meetADHD criteria as teenagers. Several algorithms guide treatment of ADHD, including the American Association of Child and Adolescent Psychiatry Practice Parameters for ADHD and the Texas Department of Health Services MedicationAlgorithm Project. Medications, including D,L-methylphenidate (MPH), dextroamphetamine, mixed amphetamine salts, and atomoxetine are FDA approved for the treatment of ADHD and considered first-line treatments. In several studies, these agents were very effective in treating symptoms ofADHD,with clinical response rates of up to 70% versus 4% to 30% with placebo. The effect size of stimulant treatment relative to placebo is 1.0. MPH and amphetamine preparations were compared and found equal in efficacy. Long-acting formulations are equal in efficacy to immediaterelease preparations and have the advantage of increasing adherence with once-daily dosing. Dosage may be titrated to After participating in this activity, the psychiatrist should be better able to:","PeriodicalId":90307,"journal":{"name":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2010-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1097/01.IDT.0000377465.94323.2d","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Psychopharm review : timely reports in psychopharmacology and device-based therapies","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/01.IDT.0000377465.94323.2d","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2
Abstract
der (ADHD) in children was analyzed in several epidemiologic studies and estimated to be approximately 7%. Follow-up studies estimate that 60% to 85% of these children will meetADHD criteria as teenagers. Several algorithms guide treatment of ADHD, including the American Association of Child and Adolescent Psychiatry Practice Parameters for ADHD and the Texas Department of Health Services MedicationAlgorithm Project. Medications, including D,L-methylphenidate (MPH), dextroamphetamine, mixed amphetamine salts, and atomoxetine are FDA approved for the treatment of ADHD and considered first-line treatments. In several studies, these agents were very effective in treating symptoms ofADHD,with clinical response rates of up to 70% versus 4% to 30% with placebo. The effect size of stimulant treatment relative to placebo is 1.0. MPH and amphetamine preparations were compared and found equal in efficacy. Long-acting formulations are equal in efficacy to immediaterelease preparations and have the advantage of increasing adherence with once-daily dosing. Dosage may be titrated to After participating in this activity, the psychiatrist should be better able to:
在几项流行病学研究中分析了儿童的der (ADHD),估计约为7%。后续研究估计,这些儿童中有60%至85%在青少年时期符合adhd标准。有几种算法指导多动症的治疗,包括美国儿童和青少年精神病学协会多动症实践参数和德克萨斯州卫生服务部门药物算法项目。药物,包括D, l -哌醋甲酯(MPH),右旋安非他明,混合安非他明盐和托莫西汀是FDA批准用于治疗多动症的一线治疗方法。在几项研究中,这些药物在治疗多动症症状方面非常有效,临床反应率高达70%,而安慰剂的临床反应率为4%至30%。兴奋剂治疗相对于安慰剂的效应量为1.0。MPH和安非他明制剂比较,发现疗效相等。长效制剂的疗效与立即释放制剂相同,并且具有每日一次给药增加依从性的优点。参加此活动后,精神科医生应能更好地: